Overview

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Status:
Terminated

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated at the MTD.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cephalon

Treatments:

Delanzomib